Vera Therapeutics, Inc. (NasdaqGM: VERA)
Health Care · Biotechnology · US
$35.27
-0.03% today · +56.5% 1Y
Vera Therapeutics, Inc. (NasdaqGM: VERA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.54B and employs 361 people.
Over the last twelve months the share price has gained 56.5%, trading between 21.15 and 56.05.
Tweenvest scores Vera Therapeutics, Inc. across four factors: quality 27/100. Its strongest factor is quality.
VERA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.54B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -5.89
- Dividend yield
- —
- Beta (5Y)
- 0.95
- 52-week high
- $56.05
- 52-week low
- $21.15
- Avg volume (3M)
- —
- Shares outstanding
- 72.06M
- Employees
- 361
- Next earnings
- —
About Vera Therapeutics, Inc.
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
- ISIN
- US92337R1014
- Founded
- 2016
- Listed since
- May 14, 2021
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.39 | +0.23% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.95 | -0.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.10 | -0.45% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.50 | -0.06% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €895.40 | +1.84% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $155.61 | -2.03% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.